Greenwich Wealth Management LLC Has $16.89 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greenwich Wealth Management LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.1% in the third quarter, Holdings Channel.com reports. The fund owned 16,067 shares of the biopharmaceutical company’s stock after selling 12 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 1.1% of Greenwich Wealth Management LLC’s portfolio, making the stock its 10th largest position. Greenwich Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $16,891,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in REGN. Norden Group LLC raised its stake in Regeneron Pharmaceuticals by 48.1% during the first quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company’s stock worth $373,000 after acquiring an additional 126 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Regeneron Pharmaceuticals by 10.7% during the first quarter. Janney Montgomery Scott LLC now owns 26,907 shares of the biopharmaceutical company’s stock worth $25,898,000 after buying an additional 2,593 shares in the last quarter. Resonant Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $320,000. GLOBALT Investments LLC GA acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $1,022,000. Finally, PDS Planning Inc grew its position in Regeneron Pharmaceuticals by 5.0% during the 1st quarter. PDS Planning Inc now owns 354 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 17 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $5.40 during trading on Friday, reaching $843.60. 1,087,285 shares of the company’s stock were exchanged, compared to its average volume of 768,492. The firm’s fifty day moving average price is $1,058.43 and its 200-day moving average price is $1,038.87. Regeneron Pharmaceuticals, Inc. has a twelve month low of $783.57 and a twelve month high of $1,211.20. The stock has a market capitalization of $93.00 billion, a PE ratio of 20.88, a PEG ratio of 2.88 and a beta of 0.15. The company has a quick ratio of 4.62, a current ratio of 5.99 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the prior year, the firm posted $8.79 EPS. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on REGN shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,090.24.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.